Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy

NMR in Biomedicine

Volumn 28, Issue 9, 2015, Pages 1150-1162

  Wary, Claire ^a,b,c   Azzabou, Noura ^a,b,c   Giraudeau, Céline ^a,b,c   Le Louër, Julien ^a,b,c   Montus, Marie ^d   Voit, Thomas ^e   Servais, Laurent ^f   Carlier, Pierre ^a,b,c  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b DIF   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d GÉNÉTHON   (France)

^e CNRS   (France)

^f Institute of Myology Clinical Trial and Database Unit   (France)

Author keywords

31P MRS; Duchenne muscular dystrophy (DMD); Fat fraction; MRI; Non ambulant; T2

Indexed keywords

ALKALINITY; DISEASE CONTROL; MAGNETIC RESONANCE IMAGING; METABOLISM; MUSCLE; NEUROMUSCULAR REHABILITATION; PIXELS;

DISEASE PROGRESSION; DUCHENNE MUSCULAR DYSTROPHIES; EXTENSOR MUSCLES; INFLAMMATORY PROCESS; INORGANIC PHOSPHATES; NON-AMBULANT; QUANTITATIVE MEASUREMENT; ^31P MRS;

PATIENT TREATMENT;

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; ESTER DERIVATIVE; PHOSPHATE; PHOSPHODIESTER; PHOSPHOMONOESTER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; FOREARM; HUMAN; INFLAMMATION; MALE; MEASUREMENT; MOBILIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; CHILD; DISEASE PROGRESSION; FOREARM; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84939258862     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3352     Document Type: Article

References (68)

1. Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul. Disord. 2014; 24: 482-491.
2. Aartsma-Rus A. Overview on DMD exon skipping. Methods Mol. Biol. 2012; 867: 97-116.
3. Nelson SF, Crosbie RH, Miceli MC, Spencer MJ. Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr. Opin. Neurol. 2009; 22: 532-538.
4. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003; 2: 731-740.
5. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJ, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378: 595-605.
6. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, Sitsen JM, Aartsma-Rus A, van Ommen GJ, Buyse G, Darin N, Verschuuren JJ, Campion GV, de Kimpe SJ, van Deutekom JC. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 2011; 364: 1513-1522.
7. Barbash IM, Cecchini S, Faranesh AZ, Virag T, Li L, Yang Y, Hoyt RF, Kornegay JN, Bogan JR, Garcia L, Lederman RJ, Kotin RM. MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Gene Ther. 2013; 20: 274-282.
8. Bish LT, Sleeper MM, Forbes SC, Wang B, Reynolds C, Singletary GE, Trafny D, Morine KJ, Sanmiguel J, Cecchini S, Virag T, Vulin A, Beley C, Bogan J, Wilson JM, Vandenborne K, Kornegay JN, Walter GA, Kotin RM, Garcia L, Sweeney HL. Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol. Ther. 2012; 20: 580-589.
9. Vulin A, Barthelemy I, Goyenvalle A, Thibaud JL, Beley C, Griffith G, Benchaouir R, le Hir M, Unterfinger Y, Lorain S, Dreyfus P, Voit T, Carlier P, Blot S, Garcia L. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol. Ther. 2012; 20: 2120-2133.
10. Le Guiner C, Montus M, Servais L, Cherel Y, Francois V, Thibaud JL, Wary C, Matot B, Larcher T, Guigand L, Dutilleul M, Domenger C, Allais M, Beuvin M, Moraux A, Le Duff J, Devaux M, Jaulin N, Guilbaud M, Latournerie V, Veron P, Boutin S, Leborgne C, Desgue D, Deschamps JY, Moullec S, Fromes Y, Vulin A, Smith RH, Laroudie N, Barnay-Toutain F, Riviere C, Bucher S, Le TH, Delaunay N, Gasmi M, Kotin RM, Bonne G, Adjali O, Masurier C, Hogrel JY, Carlier P, Moullier P, Voit T. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol. Ther. 2014; 22: 1923-1935.
11. Thibaud JL, Azzabou N, Barthelemy I, Fleury S, Cabrol L, Blot S, Carlier PG. Comprehensive longitudinal characterization of canine muscular dystrophy by serial NMR imaging of GRMD dogs. Neuromuscul. Disord. 2012; 22 (Suppl. 2): S85-S99.
12. 31P NMR anomalies of skeletal muscle metabolites in canine muscular dystrophy. NMR Biomed. 2012; 25: 1160-1169.
13. Fan Z, Wang J, Ahn M, Shiloh-Malawsky Y, Chahin N, Elmore S, Bagnell CR Jr, Wilber K, An H, Lin W, Zhu H, Styner M, Kornegay JN. Characteristics of magnetic resonance imaging biomarkers in a natural history study of golden retriever muscular dystrophy. Neuromuscul. Disord. 2014; 24: 178-191.
14. 31P spectroscopy. Neuromuscul. Disord. 2012; 22: 859.
15. Hollingsworth KG. Quantitative MRI in muscular dystrophy: an indispensable trial endpoint? Neurology 2014; 83: 956-957.
16. Kinali M, Arechavala-Gomeza V, Cirak S, Glover A, Guglieri M, Feng L, Hollingsworth KG, Hunt D, Jungbluth H, Roper HP, Quinlivan RM, Gosalakkal JA, Jayawant S, Nadeau A, Hughes-Carre L, Manzur AY, Mercuri E, Morgan JE, Straub V, Bushby K, Sewry C, Rutherford M, Muntoni F. Muscle histology vs MRI in Duchenne muscular dystrophy. Neurology 2012; 76: 346-353.
17. Fischmann A, Hafner P, Gloor M, Schmid M, Klein A, Pohlman U, Waltz T, Gonzalez R, Haas T, Bieri O, Fischer D. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J. Neurol. 2013; 260: 969-974.
18. Gaeta M, Messina S, Mileto A, Vita GL, Ascenti G, Vinci S, Bottari A, Vita G, Settineri N, Bruschetta D, Racchiusa S, Minutoli F. Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Preliminary experience. Skel. Radiol. 2012; 41: 955-961.
19. Akima H, Lott D, Senesac C, Deol J, Germain S, Arpan I, Bendixen R, Lee Sweeney H, Walter G, Vandenborne K. Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy. Neuromuscul. Disord. 2012; 22: 16-25.
20. Torriani M, Townsend E, Thomas BJ, Bredella MA, Ghomi RH, Tseng BS. Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study. Skel. Radiol. 2012; 41: 437-445.
21. Kim HK, Laor T, Horn PS, Racadio JM, Wong B, Dardzinski BJ. T2 mapping in Duchenne muscular dystrophy: distribution of disease activity and correlation with clinical assessments. Radiology 2010; 255: 899-908.
22. Kim HK, Merrow AC, Shiraj S, Wong BL, Horn PS, Laor T. Analysis of fatty infiltration and inflammation of the pelvic and thigh muscles in boys with Duchenne muscular dystrophy (DMD): grading of disease involvement on MR imaging and correlation with clinical assessments. Pediatr. Radiol. 2013; 43: 1327-1335.
23. Wren TA, Bluml S, Tseng-Ong L, Gilsanz V. Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. Am. J. Roentgenol. 2008; 190: W8-W12.
24. Hollingsworth KG, Garrood P, Eagle M, Bushby K, Straub V. Magnetic resonance imaging in Duchenne muscular dystrophy: longitudinal assessment of natural history over 18months. Muscle Nerve 2013; 48: 586-588.
25. Wokke BH, van den Bergen JC, Versluis MJ, Niks EH, Milles J, Webb AG, van Zwet EW, Aartsma-Rus A, Verschuuren JJ, Kan HE. Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. Neuromuscul. Disord. 2014; 24: 409-416.
26. Willcocks RJ, Arpan IA, Forbes SC, Lott DJ, Senesac CR, Senesac E, Deol J, Triplett WT, Baligand C, Daniels MJ, Sweeney HL, Walter GA, Vandenborne K. Longitudinal measurements of MRI-T in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul. Disord. 2014; 24: 393-401.
27. Arpan I, Willcocks RJ, Forbes SC, Finkel RS, Lott DJ, Rooney WD, Triplett WT, Senesac CR, Daniels MJ, Byrne BJ, Finanger EL, Russman BS, Wang DJ, Tennekoon GI, Walter GA, Sweeney HL, Vandenborne K. Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology 2014; 83: 974-980.
28. Azzabou N, Loureiro de Sousa P, Caldas E, Carlier PG. Validation of a generic approach to muscle water T2 determination at 3T in fat-infiltrated skeletal muscle. J. Magn. Reson. Imaging, 2014; 41: 645-653.
29. Arpan I, Forbes SC, Lott DJ, Senesac CR, Daniels MJ, Triplett WT, Deol JK, Sweeney HL, Walter GA, Vandenborne K. T(2) mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy. NMR Biomed. 2013; 26: 320-328.
30. Edwards RH, Dawson MJ, Wilkie DR, Gordon RE, Shaw D. Clinical use of nuclear magnetic resonance in the investigation of myopathy. Lancet 1982; 1: 725-731.
31. Newman RJ, Bore PJ, Chan L, Gadian DG, Styles P, Taylor D, Radda GK. Nuclear magnetic resonance studies of forearm muscle in Duchenne dystrophy. Br. Med. J. (Clin. Res. Ed) 1982; 284: 1072-1074.
32. 31P MRS study. Magn. Reson. Imaging 2010; 28: 698-707.
33. Magri F, Govoni A, D'Angelo MG, Del Bo R, Ghezzi S, Sandra G, Turconi AC, Sciacco M, Ciscato P, Bordoni A, Tedeschi S, Fortunato F, Lucchini V, Bonato S, Lamperti C, Coviello D, Torrente Y, Corti S, Moggio M, Bresolin N, Comi GP. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J. Neurol. 2011; 258: 1610-1623.
34. Humbertclaude V, Hamroun D, Bezzou K, Berard C, Boespflug-Tanguy O, Bommelaer C, Campana-Salort E, Cances C, Chabrol B, Commare MC, Cuisset JM, de Lattre C, Desnuelle C, Echenne B, Halbert C, Jonquet O, Labarre-Vila A, N'Guyen-Morel MA, Pages M, Pepin JL, Petitjean T, Pouget J, Ollagnon-Roman E, Richelme C, Rivier F, Sacconi S, Tiffreau V, Vuillerot C, Picot MC, Claustres M, Beroud C, Tuffery-Giraud S. Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur. J. Paediatr. Neurol. 2012; 16: 149-160.
35. Desguerre I, Christov C, Mayer M, Zeller R, Becane HM, Bastuji-Garin S, Leturcq F, Chiron C, Chelly J, Gherardi RK. Clinical heterogeneity of Duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS One 2009; 4: e4347.
36. Froeling M, Nederveen AJ, Heijtel DF, Lataster A, Bos C, Nicolay K, Maas M, Drost MR, Strijkers GJ. Diffusion-tensor MRI reveals the complex muscle architecture of the human forearm. J. Magn. Reson. Imaging 2012; 36: 237-248.
37. Glover GH, Schneider E. Three-point Dixon technique for true water/fat decomposition with B0 inhomogeneity correction. Magn. Reson. Med. 1991; 18: 371-383.
38. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J. Magn. Reson. 1997; 129: 35-43.
39. Stefan D, Di Cesare F, Andrasescu A, Popa E, Lazariev A, Vescovo E, Strbak O, Williams S, Starcuk Z, Cabanas M, van Ormondt D, Graveron-Demilly D. Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package. Meas. Sci. Technol. 2009; 20: 1-9.
40. 31P nuclear magnetic resonance study. Mol. Biol. Med. 1983; 1: 77-94.
41. Andrade JM, Estevez-Perez MG. Statistical comparison of the slopes of two regression lines: a tutorial. Anal. Chim. Acta, 2014; 838C: 1-12.
42. Davidson ZE, Kornberg AJ, Ryan MM, Sinclair K, Cairns A, Walker KZ, Truby H. Deletions in the dystrophin gene predict loss of ambulation before 10years of age in boys with Duchenne muscular dystrophy. Neuromuscul. Disord. 2012; 22: 835.
43. Wong B, Hu S, Morehart P, Cripe L, Walker M. Phenotypic profile of dystrophinopathy patients with deletion of exons 3-7 of the dystrophin gene. Neuromuscul. Disord. 2011; 21: 642.
44. Wokke BH, Bos C, Reijnierse M, van Rijswijk CS, Eggers H, Webb A, Verschuuren JJ, Kan HE. Comparison of Dixon and T1-weighted MR methods to assess the degree of fat infiltration in Duchenne muscular dystrophy patients. J. Magn. Reson. Imaging 2013; 38: 619-624.
45. Triplett WT, Baligand C, Forbes SC, Willcocks RJ, Lott DJ, Devos S, Pollaro J, Rooney WD, Sweeney HL, Bonnemann CG, Wang DJ, Vandenborne K, Walter GA. Chemical shift-based MRI to measure fat fractions in dystrophic skeletal muscle. Magn. Reson. Med. 2013; 72: 8-19.
46. Forbes SC, Walter GA, Rooney WD, Wang DJ, DeVos S, Pollaro J, Triplett W, Lott DJ, Willcocks RJ, Senesac C, Daniels MJ, Byrne BJ, Russman B, Finkel RS, Meyer JS, Sweeney HL, Vandenborne K. Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. Radiology 2013; 269: 198-207.
47. Finanger EL, Russman B, Forbes SC, Rooney WD, Walter GA, Vandenborne K. Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy. Phys. Med. Rehabil. Clin. N. Am. 2012; 23: 1-10, ix.
48. Servais L, Deconinck N, Moraux A, Benali M, Canal A, Van Parys F, Vereecke W, Wittevrongel S, Mayer M, Desguerre I, Maincent K, Themar-Noel C, Quijano-Roy S, Serari N, Voit T, Hogrel JY. Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul. Disord. 2013; 23: 139-148.
49. Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, Vandenhauwe M, Klingels K, Florence J, Main M, Bianco F, Henrikson E, Servais L, Campion G, Vroom E, Ricotti V, Goemans N, McDonald C, Mercuri E. Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev. Med. Child Neurol. 2013; 55: 1038-1045.
50. Willis TA, Hollingsworth KG, Coombs A, Sveen ML, Andersen S, Stojkovic T, Eagle M, Mayhew A, de Sousa PL, Dewar L, Morrow JM, Sinclair CD, Thornton JS, Bushby K, Lochmuller H, Hanna MG, Hogrel JY, Carlier PG, Vissing J, Straub V. Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One 2013; 8: e70993.
51. Carlier PG. Global T2 versus water T2 in NMR imaging of fatty infiltrated muscles: different methodology, different information and different implications. Neuromuscul. Disord. 2014; 24: 390-392.
52. Rooney W, Forbes SC, Triplett W, Wang D-J, Pollaro J, DeVos S, Willcocks RJ, Finkel R, Russman B, Byrne B, Sweeney L, Walter GA, Vandenborne K. Soleus muscle water T2 values in Duchenne muscular dystrophy: associations with age and corticosteroid treatment. Proceedings of the 21st ISMRM Scientific Meeting, Salt Lake City, UT, USA, 2013; 689.
53. Marden FA, Connolly AM, Siegel MJ, Rubin DA. Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. Skel. Radiol. 2005; 34: 140-148.
54. 31P-NMR: controlled trials show no effect of allopurinol or ribose. Muscle Nerve 1985; 8: 760-7.
55. 31P-NMR spectroscopy of skeletal muscle in Becker dystrophy and DMD/BMD carriers. Altered rate of phosphate transport. J. Neurol. Sci. 1992; 109: 188-195.
56. Kemp GJ, Taylor DJ, Dunn JF, Frostick SP, Radda GK. Cellular energetics of dystrophic muscle. J. Neurol. Sci. 1993; 116: 201-206.
57. 31P NMR studies in Duchenne muscular dystrophy: age-related metabolic changes. Neurology 1987; 37: 165-169.
58. Wokke BH, Hooijmans MT, van den Bergen JC, Webb AG, Verschuuren JJ, Kan HE. Muscle MRS detects elevated PDE/ATP ratios prior to fatty infiltration in Becker muscular dystrophy. NMR Biomed. 2014; 27: 1371-1377.
59. McCully K, Giger U, Argov Z, Valentine B, Cooper B, Chance B, Bank W. Canine X-linked muscular dystrophy studied with in vivo phosphorus magnetic resonance spectroscopy. Muscle Nerve 1991; 14: 1091-1098.
60. 31P NMR spectroscopy of forearm at rest. MAGMA 2012; 25 (Suppl. 1): 464.
61. Samaha FJ, Davis B, Nagy B. Duchenne muscular dystrophy: adenosine triphosphate and creatine phosphate content in muscle. Neurology, 1981; 31: 916-919.
62. Heerschap A, Bergman AH, van Vaals JJ, Wirtz P, Loermans HM, Veerkamp JH. Alterations in relative phosphocreatine concentrations in preclinical mouse muscular dystrophy revealed by in vivo NMR. NMR Biomed. 1988; 1: 27-31.
63. Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 1988; 52: 503-513.
64. Janssen BH, Voet NB, Nabuurs CI, Kan HE, de Rooy JW, Geurts AC, Padberg GW, van Engelen BG, Heerschap A. Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration. PLoS One 2014; 9: e85416.
65. Carlier PG, Azzabou N, Loureiro de Sousa P, Carlier R-Y, Boisserie J-M, Wary C, Orlikowski D, Laforêt P. Quantitative NMR imaging in Pompe patients to monitor the progression of skeletal muscle alterations without and with enzyme substitution therapy. Proceedings of the 22nd Scientific Meeting ISMRM, Milan, Italy, 2014; 4403.
66. 23Na) MRI detects elevated muscular sodium concentration in Duchenne muscular dystrophy. Neurology 2011; 77: 2017-2024.
67. Weber MA, Nagel AM, Wolf MB, Jurkat-Rott K, Kauczor HU, Semmler W, Lehmann-Horn F. Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: a possible contributor of progressive muscle degeneration. J. Neurol. 2012; 259: 2385-2392.
68. Lehmann-Horn F, Weber MA, Nagel AM, Meinck HM, Breitenbach S, Scharrer J, Jurkat-Rott K. Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone. Acta Myol. 2012; 31: 31-39.